The rate of infusion reactions was substantially lower in patients receiving SC compared with intravenous daratumumab.
Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care.
Lenalidomide reduced the risk of disease progression in patients with intermediate- or high-risk smoldering multiple myeloma, but discontinuation rates were high.
Patients receiving daratumumab demonstrated a statistically significant decline in pain symptoms that was sustained over time.
When added to bortezomib, thalidomide, and dexamethasone, daratumumab was associated with higher rates of measurable disease negativity.
Patients with both high and standard cytogenetic risk who received daratumumab experienced increased PFS.
Carfilzomib administered once weekly demonstrated benefit in progress-free survival independent of patient frailty.
Researchers developed a new model for risk stratification in patients with SMM based on updated criteria.
Median progression-free survival was 22.3 months in patients receiving carfilzomib and 22.1 months in patients receiving bortezomib.
Busulfan plus melphalan may be a viable pretreatment conditioning regimen for patients undergoing autologous hematopoietic stem cell transplantation.
